Proposed Revised Definitions for the Levels of Evidence for NIOSH Skin Notation Profiles; Request for Comment, 13122-13123 [2017-04628]
Download as PDF
13122
Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices
(404) 498–2741; or via email at
NAnderson@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for the Centers
for Disease Control and Prevention and
the Agency for Toxic Substances and
Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04621 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Board of Scientific Counselors,
National Institute for Occupational
Safety and Health (BSC, NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting for the
aforementioned committee:
Time and Date: 8:30 a.m.–12:45 p.m.,
EDT, April 12, 2017.
Place: 1095 Willowdale Road,
Morgantown, WV 26505. The meeting is
also available via webcast.
Status: This meeting is open to the
public, limited only by the space
available. The meeting room
accommodates approximately 50
people. The public is welcome to
participate during the public comment
period, 9:20 a.m.–9:30 a.m. EDT, April
12, 2017. Please note that the public
comment period ends at the time
indicated above or following the last
call for comments, whichever is earlier.
Members of the public who want to
comment must sign up by providing
their name by mail, email, or telephone,
at the addresses provided below by
April 7, 2017. Each commenter will be
provided up to five minutes for
comment. A limited number of time
slots are available and will be assigned
on a first come-first served basis.
Written comments will also be accepted
from those unable to attend the public
session via an on-line form at the
following Web site: https://www.cdc.gov/
niosh/bsc/contact.html. The meeting is
also open to the public via webcast. If
you wish to attend in person or by
webcast, please see the NIOSH Web site
to register (https://www.cdc.gov/niosh/
VerDate Sep<11>2014
17:43 Mar 08, 2017
Jkt 241001
bsc/) or call (404–498–2539) at least five
business days in advance of the
meeting. Teleconference is available
toll-free; please dial (888) 397–9578,
Participant Pass Code 63257516. Adobe
Connect webcast will be available at
https://odniosh.adobeconnect.com/
nioshbsc/ for participants wanting to
connect remotely.
Purpose: The Secretary, the Assistant
Secretary for Health, and by delegation
the Director, Centers for Disease Control
and Prevention, are authorized under
Sections 301 and 308 of the Public
Health Service Act to conduct directly
or by grants or contracts, research,
experiments, and demonstrations
relating to occupational safety and
health and to mine health. The Board of
Scientific Counselors provides guidance
to the Director, National Institute for
Occupational Safety and Health on
research and prevention programs.
Specifically, the Board provides
guidance on the Institute’s research
activities related to developing and
evaluating hypotheses, systematically
documenting findings and
disseminating results. The Board
evaluates the degree to which the
activities of the National Institute for
Occupational Safety and Health: (1)
Conform to appropriate scientific
standards, (2) address current, relevant
needs, and (3) produce intended results.
Matters for Discussion: NIOSH
Director’s update; occupational motor
vehicle safety, the nanotoxicolgy
program, flu-related research, and mold
investigations.
Agenda items are subject to change as
priorities dictate.
An agenda is also posted on the
NIOSH Web site (https://www.cdc.gov/
niosh/bsc/). Members of the public who
wish to address the NIOSH BSC are
requested to contact the Executive
Secretary for scheduling purposes (see
contact information below).
Alternatively, written comments to the
BSC may be submitted via an on-line
form at the following Web site: https://
www.cdc.gov/niosh/bsc/contact.html.
Contact Person for More Information:
Paul J. Middendorf, Ph.D., Executive
Secretary, BSC, NIOSH, CDC, 1600
Clifton Road NE., MS–E20, Atlanta, GA
30329–4018, telephone (404) 498–2500,
fax (404) 498–2526.
The Director, Management Analysis
and Services Office has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
[FR Doc. 2017–04620 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number CDC–2017–0017, NIOSH
153–D]
Proposed Revised Definitions for the
Levels of Evidence for NIOSH Skin
Notation Profiles; Request for
Comment
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for comments.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) proposes
to clarify the definitions for ‘sufficient’,
‘limited’, and ‘insufficient’ levels of
evidence for the designation of NIOSH
skin notations. In NIOSH Current
Intelligence Bulletin (CIB) 61—A
Strategy for Assigning New NIOSH Skin
Notations, Appendix E.2, Evaluation of
data, pp. 41–42 [https://www.cdc.gov/
niosh/docs/2009-147/pdfs/2009147.pdf] these levels of evidence are
defined as the following:
‘‘Data sets classified as sufficient are
those that include human and/or animal
toxicity studies conducted according to
standardized protocols and that provide
in-depth descriptions of the exposure
conditions and study findings. Data sets
classified as limited via the qualitative
ranking scheme contain either human
and/or animal studies conducted by
non-standardized protocols or contain
incomplete descriptions of the exposure
conditions and study findings. Data sets
classified as insufficient include studies
that primarily either did not apply
standard protocols or did not provide an
in-depth description of the exposure
conditions or study findings. Data sets
that receive the insufficient ranking will
not be used as the basis for the NIOSH
skin notation.’’
NIOSH proposes to clarify the
definitions for the sufficient, limited,
SUMMARY:
E:\FR\FM\09MRN1.SGM
09MRN1
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 82, No. 45 / Thursday, March 9, 2017 / Notices
and insufficient levels of evidence to the
following:
‘‘Data sets classified as sufficient are
those that include human and/or animal
studies conducted using standardized
protocols and that provide complete
descriptions of the exposure conditions
and study findings. Data sets classified
as limited are those that include human
and/or animal studies conducted using
non-standardized protocols or that
provide incomplete descriptions of the
exposure conditions or study findings.
Data sets classified as insufficient are
those that include human and/or animal
studies conducted using nonstandardized protocols and that provide
incomplete descriptions of the exposure
conditions and study findings. Data sets
that receive the insufficient ranking will
not be used as the basis for the NIOSH
skin notation.’’
Evaluation of dose-related effects in
studies with limited or insufficient
evidence, mechanistic data, and
analogous chemical properties may be
factored into the classification scheme
for determining the level of evidence for
identified studies. Data sets that provide
insufficient evidence will not be used as
the basis for the NIOSH skin notation
but, in some cases, may provide
information to support or contradict
evidence for the skin notation.
For data sets with conflicting
findings, an overall determination based
on the body of evidence will be
developed by evaluating data adequacy,
reliability and relevance, and assessing
each study’s quality of evidence. The
studies with the best quality and
validity to support the notation are
identified and cited in the individual
Skin Notation Profile documents.
NIOSH seeks comments on proposed
changes as described above.
DATES: Comments must be submitted on
or before April 10, 2017.
ADDRESSES: You may submit comments,
identified by CDC–2017–0017 and
docket number NIOSH 153–D, by any of
the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Instructions: All information received
in response to this notice must include
the agency name and docket number
[CDC–2017–0017; NIOSH 153–D]. All
relevant comments received will be
posted without change to
www.regulations.gov, including any
personal information provided. For
access to the docket to read background
VerDate Sep<11>2014
17:43 Mar 08, 2017
Jkt 241001
documents or comments received, go to
www.regulations.gov. For access to the
original docket [NIOSH–153] to view
background documents or comments
received, go to https://www.cdc.gov/
niosh/docket/archive/docket153.html.
All information received in response to
this notice will be available for public
examination and copying at the NIOSH
Docket Office, 1150 Tusculum Avenue,
Room 155, Cincinnati, OH 45226–1998.
FOR FURTHER INFORMATION CONTACT:
Naomi Hudson or G. Scott Dotson,
NIOSH, Education and Information
Division, Robert A. Taft Laboratories,
1190 Tusculum Ave, MS C–32,
Cincinnati, OH 45226, email: iuz8@
cdc.gov or fya8@cdc.gov.
In 2009,
NIOSH published Current Intelligence
Bulletin 61—A Strategy for assigning
New NIOSH Skin Notations [NIOSH
2009–147; https://www.cdc.gov/niosh/
docs/2009-147/pdfs/2009-147.pdf]. The
CIB presents a strategic framework that
is a form of hazard identification that
ensures that the assigned skin notations
reflect the contemporary state of
scientific knowledge, provides
transparency behind the assignment
process, communicates the hazards of
chemical exposures of the skin, and
meets the needs of health professionals,
employers, and others interested in
protecting workers from chemical
contact with the skin. Published Skin
Notation Profile documents are
available at https://www.cdc.gov/niosh/
topics/skin/skin-notation_profiles.html.
SUPPLEMENTARY INFORMATION:
Frank Hearl,
Chief of Staff, National Institute for
Occupational Safety and Health, Centers for
Disease Control and Prevention.
[FR Doc. 2017–04628 Filed 3–8–17; 8:45 am]
13123
1:00 p.m.–5:00 p.m.,
EDT, April 11, 2017 (Closed).
PLACE: Teleconference.
STATUS: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
MATTERS FOR DISCUSSION: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Cooperative Agreement on Global
Occupational Health with the World
Health Organization (WHO)’’, RFA–
OH17–1701.
CONTACT PERSON FOR MORE INFORMATION:
Nina Turner, Ph.D., Scientific Review
Officer, NIOSH, CDC, 1095 Willowdale
Road, Mailstop G905, Morgantown,
West Virginia 26506, Telephone: (304)
285–5976.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
TIME AND DATE:
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–04626 Filed 3–8–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention (CDC)
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
RFA–OH17–1701, Cooperative
Agreement on Global Occupational
Health with the World Health
Organization (WHO).
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Time and Date: 8:30 a.m.–3:00 p.m.,
EDT, April 20, 2017.
Place: CDC, Building 19, Auditorium
B3, 1600 Clifton Road NE., Atlanta,
Georgia 30329.
Status: Open to the public, limited
only by the seating and phone lines
available. The meeting room
accommodates approximately 60
people. Advance registration for in-
E:\FR\FM\09MRN1.SGM
09MRN1
Agencies
[Federal Register Volume 82, Number 45 (Thursday, March 9, 2017)]
[Notices]
[Pages 13122-13123]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04628]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number CDC-2017-0017, NIOSH 153-D]
Proposed Revised Definitions for the Levels of Evidence for NIOSH
Skin Notation Profiles; Request for Comment
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Request for comments.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC)
proposes to clarify the definitions for `sufficient', `limited', and
`insufficient' levels of evidence for the designation of NIOSH skin
notations. In NIOSH Current Intelligence Bulletin (CIB) 61--A Strategy
for Assigning New NIOSH Skin Notations, Appendix E.2, Evaluation of
data, pp. 41-42 [https://www.cdc.gov/niosh/docs/2009-147/pdfs/2009-147.pdf] these levels of evidence are defined as the following:
``Data sets classified as sufficient are those that include human
and/or animal toxicity studies conducted according to standardized
protocols and that provide in-depth descriptions of the exposure
conditions and study findings. Data sets classified as limited via the
qualitative ranking scheme contain either human and/or animal studies
conducted by non-standardized protocols or contain incomplete
descriptions of the exposure conditions and study findings. Data sets
classified as insufficient include studies that primarily either did
not apply standard protocols or did not provide an in-depth description
of the exposure conditions or study findings. Data sets that receive
the insufficient ranking will not be used as the basis for the NIOSH
skin notation.''
NIOSH proposes to clarify the definitions for the sufficient,
limited,
[[Page 13123]]
and insufficient levels of evidence to the following:
``Data sets classified as sufficient are those that include human
and/or animal studies conducted using standardized protocols and that
provide complete descriptions of the exposure conditions and study
findings. Data sets classified as limited are those that include human
and/or animal studies conducted using non-standardized protocols or
that provide incomplete descriptions of the exposure conditions or
study findings. Data sets classified as insufficient are those that
include human and/or animal studies conducted using non-standardized
protocols and that provide incomplete descriptions of the exposure
conditions and study findings. Data sets that receive the insufficient
ranking will not be used as the basis for the NIOSH skin notation.''
Evaluation of dose-related effects in studies with limited or
insufficient evidence, mechanistic data, and analogous chemical
properties may be factored into the classification scheme for
determining the level of evidence for identified studies. Data sets
that provide insufficient evidence will not be used as the basis for
the NIOSH skin notation but, in some cases, may provide information to
support or contradict evidence for the skin notation.
For data sets with conflicting findings, an overall determination
based on the body of evidence will be developed by evaluating data
adequacy, reliability and relevance, and assessing each study's quality
of evidence. The studies with the best quality and validity to support
the notation are identified and cited in the individual Skin Notation
Profile documents.
NIOSH seeks comments on proposed changes as described above.
DATES: Comments must be submitted on or before April 10, 2017.
ADDRESSES: You may submit comments, identified by CDC-2017-0017 and
docket number NIOSH 153-D, by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: National Institute for Occupational Safety and
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati,
Ohio 45226-1998.
Instructions: All information received in response to this notice
must include the agency name and docket number [CDC-2017-0017; NIOSH
153-D]. All relevant comments received will be posted without change to
www.regulations.gov, including any personal information provided. For
access to the docket to read background documents or comments received,
go to www.regulations.gov. For access to the original docket [NIOSH-
153] to view background documents or comments received, go to https://www.cdc.gov/niosh/docket/archive/docket153.html. All information
received in response to this notice will be available for public
examination and copying at the NIOSH Docket Office, 1150 Tusculum
Avenue, Room 155, Cincinnati, OH 45226-1998.
FOR FURTHER INFORMATION CONTACT: Naomi Hudson or G. Scott Dotson,
NIOSH, Education and Information Division, Robert A. Taft Laboratories,
1190 Tusculum Ave, MS C-32, Cincinnati, OH 45226, email: iuz8@cdc.gov
or fya8@cdc.gov.
SUPPLEMENTARY INFORMATION: In 2009, NIOSH published Current
Intelligence Bulletin 61--A Strategy for assigning New NIOSH Skin
Notations [NIOSH 2009-147; https://www.cdc.gov/niosh/docs/2009-147/pdfs/2009-147.pdf]. The CIB presents a strategic framework that is a form of
hazard identification that ensures that the assigned skin notations
reflect the contemporary state of scientific knowledge, provides
transparency behind the assignment process, communicates the hazards of
chemical exposures of the skin, and meets the needs of health
professionals, employers, and others interested in protecting workers
from chemical contact with the skin. Published Skin Notation Profile
documents are available at https://www.cdc.gov/niosh/topics/skin/skin-notation_profiles.html.
Frank Hearl,
Chief of Staff, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2017-04628 Filed 3-8-17; 8:45 am]
BILLING CODE 4163-18-P